Research Progress of SGLT2 Inhibitors in the Treatment of Acute Heart Failure: A Narrative Review Authors: Xiaoying Wang, Yuanyuan Ning, Xiaojuan Wang, Guangli Li, Xiaowu Wang, Dong Wu Published: 2026 ABSTRACT AbstractAcute heart failure (AHF) is the main cause of hospitalization in patients with heart failure (HF). Although traditional therapies play an important role in symptom relief, their efficacy in reducing mortality, rehospitalization rates, and improving long-term prognosis remains unsatisfactory. In recent years, sodium‑glucose cotransporter 2 (SGLT2) inhibitors, originally developed as glucose‑lowering agents, have demonstrated significant benefits in chronic heart failure, and their potential utility in AHF is attracting increasing attention. Current evidence indicates that early initiation of SGLT2 inhibitors in patients with AHF is generally safe, improving diuretic efficiency, relieving congestion, and reducing the risk of heart failure events. However, findings on short‑term readmission rates remain inconsistent across studies. Furthermore, unresolved issues persist regarding the optimal timing of initiation and safety in specific patient populations. This narrative review summarizes the available evidence up to 31 March 2026, with emphasis on key clinical trials, including DAPA ACT HF-TIMI 68, and selected real-world studies. We discuss the potential benefits, safety considerations, unresolved controversies, and evidence gaps regarding the use of SGLT2 inhibitors in AHF, aiming to provide a clinically oriented reference for future research and practice. Introduction Acute heart failure (AHF) is a severe pathophysiologic condition in which cardiac dysfunction renders blood flow insufficient to meet tissue metabolic demands.1 Clinically it is characterized by dyspnea, orthopnea, lower-limb edema, elevated jugular venous pressure and pulmonary congestion.2 AHF is the leading cause of hospital admission for heart-failure patients, with 30-day mortality of 15–25% and a 1-year readmission rate >40%.3 Other data show 2-year mortality as high as 52.8%.4 Because of its high morbidity and mortality, prompt intervention is required to prevent serious complications.1 Current in-hospital therapy is aimed chiefly at symptom relief-loop diuretics to reduce volume load, vasodilators to decrease cardiac filling pressures, and inotropes to support pump function.5 These measures, however, especially conventional loop diuretics, afford rapid symptomatic benefit but do not improve long-term prognosis; they may even exert adverse effects by activating neuro-hormonal systems such as the renin-angiotensin-aldosterone axis (RAAS) and by provoking electrolyte disturbances. Sodium glucose cotransporter 2 (SGLT2) inhibitors, which increase urinary glucose excretion by acting on renal receptors, are widely used to treat type 2 diabetes. Studies have shown that, beyond glycemic control, SGLT2 inhibitors lower the incidence and mortality of cardiovascular disease, reduce hospitalizations, and improve survival in heart-failure patients, making them a viable therapeutic option for heart failure.6,7 The landmark DAPA-HF and DELIVER trial subsequently demonstrated significant reductions in cardiovascular death and worsening heart failure in chronic heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), establishing SGLT2 inhibitors as cornerstone therapy for chronic heart failure.8,9 Evidence for their use in AHF remains limited and conflicting. Although previous reviews have summarized randomized controlled trial evidence on SGLT2 inhibitors in AHF, several clinically relevant questions remain unresolved.10 First, recently published trials and real-world studies have expanded the evidence base, but their findings regarding early clinical outcomes, especially short-term readmission, are not entirely consistent. Second, the optimal timing of initiation after admission or around discharge remains uncertain, and the definition of haemodynamic stabilization varies across studies and guidelines. Third, evidence regarding safety in high-risk populations, such as patients with severe renal impairment, cardiogenic shock, or those requiring vasoactive support, remains limited. Therefore, this narrative review summarizes and discusses available evidence up to 31 March 2026, with particular attention to clinical efficacy, safety, timing of initiation, and remaining evidence gaps, aiming to provide a clinically oriented reference for future research and practice. A schematic overview of the clinical context, timing of initiation, potential benefits, safety considerations, and remaining uncertainties of SGLT2 inhibitors in AHF is presented in Figure 1.Figure 1Overview of SGLT2 inhibitors in acute heart failure. For selected haemodynamically stabilized patients, early SGLT2 inhibitor initiation offers decongestive, diuretic, and cardiorenal benefits possibly via osmotic diuresis, natriuresis, metabolic, and anti-inflammatory mechanisms, though optimal timing, high-risk safety, and readmission effects remain uncertain.Infographic on early SGLT2 inhibitor use in acute heart failure, benefits, safety and uncertainties.The infographic illustrates the use of early SGLT2 inhibitor initiation in acute heart failure (AHF) after hemodynamic stabilization. It highlights symptoms like pulmonary congestion, dyspnea, edema and fluid overload. Early SGLT2 inhibitor initiation shows no significant hypotension, no vasoactive support, stable renal function, no ketoacidosis and no severe genitourinary infection. Benefits include decongestion with increased urine output and improved diuretic efficiency, clinical benefits with reduced heart failure events and cardiorenal safety with generally preserved renal function. Potential mechanisms involve osmotic diuresis, natriuresis, reduced congestion, improved myocardial energy metabolism and anti-inflammatory effects. Remaining uncertainties include unclear optimal timing, need for more evidence on safety in high-risk patients and inconsistent short-term readmission results. Overview of SGLT2 inhibitors in acute heart failure. For selected haemodynamically stabilized patients, early SGLT2 inhibitor initiation offers decongestive, diuretic, and cardiorenal benefits possibly via osmotic diuresis, natriuresis, metabolic, and anti-inflammatory mechanisms, though optimal timing, high-risk safety, and readmission effects remain uncertain. Literature Search and Study Selection We conducted a narrative literature review to summarize current evidence regarding the efficacy, timing of initiation, safety, and clinical implementation of sodium-glucose cotransporter 2 (SGLT2) inhibitors in acute heart failure (AHF). PubMed, Web of Science, and the Cochrane Library were searched from database inception to 31 March 2026. The following search terms were used alone or in combination: “SGLT2 inhibitors,” “sodium-glucose cotransporter 2 inhibitors,” “dapagliflozin,” “empagliflozin,” “canagliflozin,” “ertugliflozin,” “sotagliflozin,” “luseogliflozin,” “ipragliflozin,” “tofogliflozin,” “remogliflozin,” “acute heart failure,” “acute decompensated heart failure,” “worsening heart failure,” “hospitalized heart failure,” and “AHF.” Reference lists of relevant articles, guidelines, and reviews were also screened to identify additional eligible studies. We considered randomized controlled trials, prespecified trial subanalyses, observational cohort studies, registry-based studies, real-world studies, meta-analyses, guideline documents, and major review articles that evaluated or discussed SGLT2 inhibitors in patients with AHF or recent worsening heart failure. Studies were prioritized if they reported clinically relevant outcomes, including decongestion, diuretic response, renal function, hypotension, ketoacidosis, genitourinary infections, heart failure events, readmission, mortality, treatment discontinuation, or timing of treatment initiation. Articles were excluded if they focused exclusively on stable chronic heart failure, diabetes without heart failure outcomes, preclinical mechanisms without clinical relevance to AHF, or did not provide sufficient information related to SGLT2 inhibitors in the acute or peri-discharge setting. Two authors (XyW and YyN) independently screened titles, abstracts, and full texts for relevance. Disagreements were resolved through discussion with a third author (DW). Because this article is a narrative review rather than a formal systematic review or meta-analysis, no protocol registration, formal PRISMA-based study selection process, quantitative evidence synthesis, or formal risk-of-bias assessment was performed. However, greater weight was given to randomized controlled trials, large observational studies, guideline recommendations, and studies with clearly defined populations, interventions, outcomes, and follow-up periods. To improve interpretability, the clinical evidence was subsequently organized according to study design and clinical question, with separate discussion of randomized controlled trials, trial subanalyses and meta-analytic evidence, real-world and observational evidence, timing of initiation, safety considerations, and guideline recommendations. Clinical Evidence, Timing of Initiation, and Safety of SGLT2 Inhibitors in AHF As shown in Table 1, current evidence regarding SGLT2 inhibitors in AHF includes randomized controlled trials, prespecified trial subanalyses, observational studies, registry-based cohorts, and guideline recommendations. Because these sources differ substantially in study design, patient selection, timing of initiation, endpoints, and follow-up duration, the strength of evidence varies across clinical questions. Therefore, this section is organized according to evidence type and clinical question to facilitate a balanced interpretation of efficacy, timing, safety, and remaining uncertainties. Table 1Summary of Key Clinical Evidence for SGLT2 Inhibitors in Acute or Recently Worsening Heart FailureStudyPublication YearPopulationSample SizeType of SGLT2 InhibitionComparison GroupsMethod of Initiating SGLT2 InhibitionsDesignFollow UpPrimary OutcomesSecondary OutcomesEMPAG-HF112022ADHF60 (30 empagliflozin, 30 placebo; 29 placebo analyzed)EmpagliflozinEmpagliflozin 25 mg daily vs placeboWithin 12 hours of hospitalizationSingle-center, prospective, double-blind, placebo-controlled, randomized5 days (in-hospital); safety follow-up at 30 daysCumulative urine output over 5 days: empagliflozin median 10,775 mL vs placebo 8,650 mL; group difference 2,125 mL (95% CI 840–3,550), P=0.003 (25% increase)Diuretic efficiency: empagliflozin 14.1 mL urine per mg furosemide equivalent (95% CI 0.6–27.7), P=0.041; NT-proBNP reduction: empagliflozin −1,861 vs placebo −727.2 pg/mL after 5 days, quotient in slope 0.89 (95% CI 0.83–0.95), P<0.001; eGFR: no significant difference between groups (P=0.599); urinary total protein (P=0.975) and α1-microglobulin (P=0.066); safety events: no significant differences; 30-day mortality: empagliflozin 1 (3.3%) vs placebo 2 (6.9%)EMPA-RESPONSE-AHF122020ADHF, with or without diabetes80 (79 analyzed)EmpagliflozinEmpagliflozin 10 mg vs placeboWithin 24 hours of presentationRandomized, double-blind, placebo-controlled, multicenter pilot60 daysVAS dyspnea AUC over the first 4 days: 1264±1211 vs 1650±1240 mm×h, P=0.18; diuretic response: −0.35±0.44 vs −0.12±1.52 kg/40 mg furosemide, P=0.37; NT-proBNP % change: −46±32% vs −42±31%, P=0.63; length of stay: 8 (6–10) vs 8 (6–9) days, P=0.58Composite of in-hospital worsening HF, rehospitalization for HF, or death at 60 days: 10% vs 33%, P=0.014; cumulative urine output at day 4: significantly greater with empagliflozin (difference 3449 mL, 95% CI 578–6321 mL, P<0.01); safety similar between groupsEMPULSE132022Patients hospitalized for AHF (de novo or decompensated chronic), regardless of LVEF530EmpagliflozinEmpagliflozin 10 mg vs placeboInitiated in-hospital after stabilization (median 3 days after admission)Multicenter, randomized, double-blind, placebo-controlled90 daysStratified win ratio for hierarchical composite (death, HF events, KCCQ-TSS change): 1.36 (95% CI 1.09–1.68), P=0.0054Cardiovascular death or HF hospitalization: HR 0.69 (95% CI 0.45–1.08); KCCQ-TSS adjusted mean difference: +4.45 points (95% CI 0.32–8.59); NT-proBNP AUC ratio at day 30: 0.90 (95% CI 0.82–0.98); serious AEs: 32.3% vs 43.6%SOLOIST-WHF142021Type 2 diabetes patients with recent worsening heart failure1222SotagliflozinSotagliflozin 200–400 mg vs placeboBefore discharge (48.8%) or within 3 days after discharge (51.2%)Multicenter, randomized, double-blind, placebo-controlledMedian 9.0 monthsTotal number of CV deaths, hospitalizations for HF, and urgent visits for HF: rate 51.0 vs 76.3 per 100 patient-years, HR 0.67 (95% CI 0.52–0.85), P<0.001CV death: HR 0.84 (95% CI 0.58–1.22); all-cause death: HR 0.82 (95% CI 0.59–1.14); hospitalization or urgent visit for HF: HR 0.64 (95% CI 0.49–0.83); KCCQ-12 change: +4.1 points (95% CI 1.3–7.0); severe hypoglycemia: 1.5% vs 0.3%DAPA-RESPONSE-AHF152023AHF with dyspnea and congestion, with or without diabetes87DapagliflozinDapagliflozin 10 mg vs placeboWithin 24 hours of admissionRandomized, double-blind, placebo-controlled30 daysAUC of VAS dyspnea score over first 4 days: dapagliflozin 3192.2±1631.9 mm×h vs placebo 4713.1±1714.9 mm×h, P<0.001NT-proBNP % change at day 4: −34.89% vs −10.085%, P=0.001; cumulative urine output at day 4: 18600 mL vs 13700 mL, P=0.031; 30-day readmission: lower with dapagliflozin; safety similar between groupsDICTATE-AHF162024Acute hypervolemic heart failure patients (with or without diabetes)240 (238 analyzed)DapagliflozinDapagliflozin 10 mg vs structured usual care with protocolized diuretic titrationWithin 24 hours of hospital presentationMulticenter, open-label, randomized5 days or dischargeDiuretic efficiency (cumulative weight change per cumulative loop diuretic dose): adjusted OR 0.65 (95% CI 0.41–1.02), P=0.06Loop diuretic dose: 560 mg vs 800 mg, P=0.006; 24-hour natriuresis: 50 vs 35 mmol sodium/40 mg furosemide, P=0.025; 24-hour urine output: 634 vs 403 mL/40 mg furosemide, P=0.005; expedited hospital discharge (P=0.007); safety events similarDAPA ACT HF-TIMI 68172025Patients hospitalized for HF (primary diagnosis)2401DapagliflozinDapagliflozin 10 mg vs placeboInitiated in-hospital after stabilization (median 3.6 days after admission)Multicenter, randomized, double-blind, placebo-controlled2 monthsComposite of cardiovascular death or worsening heart failure: 10.9% vs 12.7%, HR 0.86 (95% CI 0.68–1.08), P=0.20All-cause death: 3.0% vs 4.5%, HR 0.66 (95% CI 0.43–1.00); symptomatic hypotension: 3.6% vs 2.2%; worsening kidney function: 5.9% vs 4.7%; meta-analysis of in-hospital SGLT2 inhibition initiation: HR for CV death or worsening HF 0.71 (95% CI 0.54–0.93), P=0.012Yeoh et al182023HF with loop diuretic resistance61 (60 analyzed)DapagliflozinDapagliflozin 10 mg vs metolazone 5–10 mgAfter randomization, administered for 3 daysMulticenter, open-label, randomized active-comparator5 days (96 hours)Weight loss at 96h: dapagliflozin −3.0±2.5 kg vs metolazone −3.6±2.0 kg; mean difference 0.65 kg (95% CI −0.12 to 1.41), P=0.11Loop diuretic efficiency (kg/40mg furosemide) at 96h: 0.15±0.12 vs 0.25±0.19, difference −0.08 (−0.17 to 0.01), P=0.10; B-line change: similar; pleural effusion score: similar; safety: less biochemical upset with dapagliflozin (urea and sodium changes significantly smaller)EL-Gazar et al192025AHF with volume overload142 (135 analyzed)Canagliflozin vs EmpagliflozinCanagliflozin 100 mg vs empagliflozin 10 mgWithin 24 hours of admissionMulticenter, prospective, open-label, randomized equivalence trial90 daysMedian daily diuresis: canagliflozin 4200 mL (IQR 3492–4963) vs empagliflozin 4117 mL (3400–5242); median difference 83 mL (95% CI −200 to +366), within equivalence margin ±411.7 mL, bootstrap TOST P<0.001NT-proBNP at discharge (median): canagliflozin 2523 pg/mL vs empagliflozin 3121, P=0.052; at day 30: 1098 vs 1768, P=0.025; KCCQ-TSS change at day 90: +28.61±21.15 vs +20.41±23.02, P=0.044; HF events: 23.9% vs 27%, P=0.684; safety similarMocan et al202025AHF100 (98 analyzed)DapagliflozinDapagliflozin + IV furosemide vs IV furosemide aloneWithin 24 hours of admissionSingle-center, open-label, randomized controlled1 monthChange in lung B-lines at discharge: dapagliflozin −23.80±14.03 vs control −13.96±10.55, P<0.001; at 1 month: −23.80±14.04 vs −13.96±10.55, P<0.001. Weight change: −5.73±5.88 kg vs −4.72±4.91 kg, P=0.10824-h natriuresis: dapagliflozin 248.03±23.69 vs 173.83±20.76, P=0.009; WRF (≥25% creatinine increase): 30.6% vs 12.8%, P=0.048; 1-month EF change: +5.99±10.07% vs +1.46±7.47%, P=0.003; EDV change: −12.54±34.81 vs −4.21±30.91, P=0.033Bogoviku et al212025ADHF60EmpagliflozinEmpagliflozin 25 mg vs placeboWithin 12 hours of admission, for 5 daysProspective, double-blind, randomized, placebo-controlled30 daysSerum uric acid (µmol/L): placebo increased from 488 to 518 at day 4; empagliflozin decreased from 458 to 423 at day 4; day 3 difference P=0.049, day 4 P=0.021, day 5 P=0.037FEUA at day 3: empagliflozin 9.38±1.07% vs placebo 5.49±0.81%, P=0.008; at day 5: 9.71±1.2% vs 8.17±1.1%, P=NS; at 30 days: both similar to baselineBogoviku et al222025ADHF60EmpagliflozinEmpagliflozin 25 mg/day vs placeboWithin 12 hours of admission, for 5 daysSingle-center, prospective, double-blind, randomized, placebo-controlled30 daysLAV reduction:empagliflozin (30.9±27.4; 95% CI 20.1–41.7) vs placebo (10.5 ± 26; 95% CI 0.4–20.5), P<0.001; LAESVI reduction:empagliflozin (15.7±15.2;95% CI9.8–21.6) vs placebo (9.7 ± 10.2; 95% CI 5.7–13.6), P=0.016LVEF: P=0.787; TAPSE: P=0.077; sPAP: P=0.335; E-wave: P=0.229; left atrial strain: P=0.361; all not statistically significantAngermann et al232026AHF (NHF and ADHF)530 (175 NHF, 355 ADHF)EmpagliflozinEmpagliflozin 10 mg vs placeboAfter stabilization, between 24h and 5 days after admission,afterclinical stabilizationMulticenter, randomized, double-blind, placebo-controlledDays 3 and 5 (if still hospitalized), andthen 15, 30, and 90 days after randomizationWin ratio for clinical benefit: NHF 1.29 (95% CI 0.89–1.89); ADHF 1.39 (95% CI 1.07–1.81); Pinteraction = 0.759Diuretic response at day 15 (kg weight loss per mean daily loop diuretic dose): NHF −5.11 (95% CI −7.89 to −2.32) vs ADHF −0.97 (−2.91 to 0.96), Pinteraction=0.017; KCCQ-TSS change at day 90: NHF +2.54 (−4.55 to 9.64), ADHF +5.29 (0.23–10.36); NT-proBNP AUC ratio at day 30: NHF 0.87 (0.75–1.01), ADHF 0.91 (0.82–1.02); safety: fewer AEs with empagliflozinHacil et al242025Elderly patients (mean age 90 years) hospitalized for AHF496Empagliflozin, DapagliflozinSGLT2 inhibition group (n=260) vs Control group (n=236, standard HF treatment without SGLT2 inhibition)Initiated during hospitalization (at discharge)Prospective multicenter observational1 yearAll-cause mortality at 1 year: 28.0% vs 36.8%, adjusted HR 0.67 (95% CI 0.46–0.98), P=0.031; HF rehospitalization: 18.0% vs 30.9%, adjusted HR 0.64 (95% CI 0.42–0.97), P=0.037; composite outcome: 38.4% vs 56.7%, adjusted HR 0.60 (95% CI 0.44–0.82), P=0.001Adverse events: urinary tract infections (14.6% vs 8.9%, OR 1.81, P=0.038), genital infections (7.6% vs 3.5%, OR 2.44, P=0.033); acute renal failure (13.1% vs 14.8%, P=0.58); treatment discontinuation due to adverse events: 5.0% (2.7% due to recurrent genitourinary infections)Mizobuchi et al252023AHF118DapagliflozinEarly initiation (≤6 days after admission) vs late initiation (≥7 days)Initiated during hospitalization at physician’s discretionPost hoc analysis of prospective observational registryin-hospitalLength of hospital stay: early group median 16.5 days (IQR 13–22) vs late group 22 days (IQR 17–27), P=0.002; time to initiation positively correlated with hospital stay (r=0.46, P<0.001)Composite event of rehospitalization for HF and all-cause death at 30 and 90 days: no significant difference between groups (P=0.26 and P=0.83)Wu et al262025AHF with type 2 diabetes (age ≥66)9641SGLT2 inhibition (canagliflozin, dapagliflozin, empagliflozin)Post-discharge SGLT2 inhibitor initiation within 3 days, 4–90 days, or91–180 days, vs delayed initiation for at least 180 days.Timing of initiation: ≤3 days, 4–90 days, 91–180 days vs delayed >180 days post-dischargePopulation-based retrospective cohort (clone-censor-weight approach)1 yearComposite of HHF or CV mortality: ≤3 days vs >180 days: RR 0.65 (95% CI 0.45–0.83); 4–90 days: RR 0.83 (0.72–0.93); 91–180 days: RR 0.89 (0.79–0.97)HHF alone: ≤3 days RR 0.55 (0.34–0.77); CV mortality: ≤3 days RR 0.67 (0.37–1.03); all-cause mortality: ≤3 days RR 0.66 (0.41–0.93); all-cause readmission: ≤3 days RR 0.74 (0.63–0.86)Llorens et al272025AHF3554SGLT2 inhibition (dapagliflozin, empagliflozin)SGLT2 inhibition use at discharge vs no use; new initiation vs chronic usePrescription at discharge after AHF episodeMulticenter, prospective, observational1 year30-day composite adverse event (ED revisit, HF hospitalization, or death): adjusted HR 0.80 (95% CI 0.65–0.99); 1-year mortality: adjusted HR 0.78 (0.63–0.96)New initiation during decompensation: 30-day composite HR 0.65 (0.49–0.87); 1-year mortality HR 0.71 (0.54–0.93); interaction P for 30-day benefit better with new initiation (P=0.02)Carballo et al282020Consecutive patients admitted for ADHF815Dapagliflozin (eligibility criteria based on DAPA-HF)Eligible for dapagliflozin (n=220, LVEF<40% meeting DAPA-HF criteria) vs non-eligible (n=595)/Prospective observational cohortMedian 15 months (IQR 7–25)All-cause mortality or readmission: eligible vs non-eligible, adjusted HR 0.82 (95% CI 0.68–0.999), P=0.049Proportion eligible for dapagliflozin: 27% of all patients; baseline characteristics: eligible patients younger (median 74.4 years), higher eGFR (55 mL/min), higher NT-proBNP (6625 ng/L) vs non-eligibleWu et al292024AHF or acute exacerbation of chronic HF399 (320 after PSM)DapagliflozinDapagliflozin group vs Dapagliflozin-Free groupInitiated within 6 days after admissionRetrospective propensity score-matched cohort90 daysAll-cause readmission at 90 days after PSM: 16.88% vs 18.12%, OR 0.9141 (95% CI 0.5385–1.552), log-rank P=0.739; HF readmission: 11.88% vs 15.00%, OR 0.9077 (95% CI 0.4441–1.469), log-rank P=0.484Loop diuretic daily dose: 20 mg/d vs 30 mg/d, P<0.001; total loop diuretic dose during hospitalization: 106.06±31.23 mg vs 144.50±45.39 mg, P=0.038; adding another class of diuretic: 11.88% vs 23.12%, P=0.008; safety events (renal function deterioration, symptomatic hypotension, hypoglycemia, ketoacidosis) similar between groupsAbbreviations:AHF, acute heart failure; HF:heart failure, ADHF, acute decompensated heart failure; SGLT2, sodium-glucose cotransporter 2; CV, cardiovascular; LVEF, left ventricular ejection fraction; NHF, de novo heart failure; HHF, hospitalization for heart failure; FEUA, fractional excretion of uric acid; ED, emergency departments; VAS, visual analogue scale; IV, intravenous; IQR, interquartile range; PSM, propensity score matching; AUC, area under the curve; NT-proBNP, N-terminalpro-B-type natriuretic peptide; 95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio; WRF, worsening renal function; EF, ejection fraction; EDV, end-diastolic volume; RR, risk ratio; TAPSE, tricuspid annular plane systolic excursion; sPAP, systolic pulmonary artery pressure; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire total symptom score; FEUA, fractional excretion of uric acid; HR, hazard ratio. Table 1Summary of Key Clinical Evidence for SGLT2 Inhibitors in Acute or Recently Worsening Heart FailureStudyPublication YearPopulationSample SizeType of SGLT2 InhibitionComparison GroupsMethod of Initiating SGLT2 InhibitionsDesignFollow UpPrimary OutcomesSecondary OutcomesEMPAG-HF112022ADHF60 (30 empagliflozin, 30 placebo; 29 placebo analyzed)EmpagliflozinEmpagliflozin 25 mg daily vs placeboWithin 12 hours of hospitalizationSingle-center, prospective, double-blind, placebo-controlled, randomized5 days (in-hospital); safety follow-up at 30 daysCumulative urine output over 5 days: empagliflozin median 10,775 mL vs placebo 8,650 mL; group difference 2,125 mL (95% CI 840–3,550), P=0.003 (25% increase)Diuretic efficiency: empagliflozin 14.1 mL urine per mg furosemide equivalent (95% CI 0.6–27.7), P=0.041; NT-proBNP reduction: empagliflozin −1,861 vs placebo −727.2 pg/mL after 5 days, quotient in slope 0.89 (95% CI 0.83–0.95), P<0.001; eGFR: no significant difference between groups (P=0.599); urinary total protein (P=0.975) and α1-microglobulin (P=0.066); safety events: no significant differences; 30-day mortality: empagliflozin 1 (3.3%) vs placebo 2 (6.9%)EMPA-RESPONSE-AHF122020ADHF, with or without diabetes80 (79 analyzed)EmpagliflozinEmpagliflozin 10 mg vs placeboWithin 24 hours of presentationRandomized, double-blind, placebo-controlled, multicenter pilot60 daysVAS dyspnea AUC over the first 4 days: 1264±1211 vs 1650±1240 mm×h, P=0.18; diuretic response: −0.35±0.44 vs −0.12±1.52 kg/40 mg furosemide, P=0.37; NT-proBNP % change: −46±32% vs −42±31%, P=0.63; length of stay: 8 (6–10) vs 8 (6–9) days, P=0.58Composite of in-hospital worsening HF, rehospitalization for HF, or death at 60 days: 10% vs 33%, P=0.014; cumulative urine output at day 4: significantly greater with empagliflozin (difference 3449 mL, 95% CI 578–6321 mL, P<0.01); safety similar between groupsEMPULSE132022Patients hospitalized for AHF (de novo or decompensated chronic), regardless of LVEF530EmpagliflozinEmpagliflozin 10 mg vs placeboInitiated in-hospital after stabilization (median 3 days after admission)Multicenter, randomized, double-blind, placebo-controlled90 daysStratified win ratio for hierarchical composite (death, HF events, KCCQ-TSS change): 1.36 (95% CI 1.09–1.68), P=0.0054Cardiovascular death or HF hospitalization: HR 0.69 (95% CI 0.45–1.08); KCCQ-TSS adjusted mean difference: +4.45 points (95% CI 0.32–8.59); NT-proBNP AUC ratio at day 30: 0.90 (95% CI 0.82–0.98); serious AEs: 32.3% vs 43.6%SOLOIST-WHF142021Type 2 diabetes patients with recent worsening heart failure1222SotagliflozinSotagliflozin 200–400 mg vs placeboBefore discharge (48.8%) or within 3 days after discharge (51.2%)Multicenter, randomized, double-blind, placebo-controlledMedian 9.0 monthsTotal number of CV deaths, hospitalizations for HF, and urgent visits for HF: rate 51.0 vs 76.3 per 100 patient-years, HR 0.67 (95% CI 0.52–0.85), P<0.001CV death: HR 0.84 (95% CI 0.58–1.22); all-cause death: HR 0.82 (95% CI 0.59–1.14); hospitalization or urgent visit for HF: HR 0.64 (95% CI 0.49–0.83); KCCQ-12 change: +4.1 points (95% CI 1.3–7.0); severe hypoglycemia: 1.5% vs 0.3%DAPA-RESPONSE-AHF152023AHF with dyspnea and congestion, with or without diabetes87DapagliflozinDapagliflozin 10 mg vs placeboWithin 24 hours of admissionRandomized, double-blind, placebo-controlled30 daysAUC of VAS dyspnea score over first 4 days: dapagliflozin 3192.2±1631.9 mm×h vs placebo 4713.1±1714.9 mm×h, P<0.001NT-proBNP % change at day 4: −34.89% vs −10.085%, P=0.001; cumulative urine output at day 4: 18600 mL vs 13700 mL, P=0.031; 30-day readmission: lower with dapagliflozin; safety similar between groupsDICTATE-AHF162024Acute hypervolemic heart failure patients (with or without diabetes)240 (238 analyzed)DapagliflozinDapagliflozin 10 mg vs structured usual care with protocolized diuretic titrationWithin 24 hours of hospital presentationMulticenter, open-label, randomized5 days or dischargeDiuretic efficiency (cumulative weight change per cumulative loop diuretic dose): adjusted OR 0.65 (95% CI 0.41–1.02), P=0.06Loop diuretic dose: 560 mg vs 800 mg, P=0.006; 24-hour natriuresis: 50 vs 35 mmol sodium/40 mg furosemide, P=0.025; 24-hour urine output: 634 vs 403 mL/40 mg furosemide, P=0.005; expedited hospital discharge (P=0.007); safety events similarDAPA ACT HF-TIMI 68172025Patients hospitalized for HF (primary diagnosis)2401DapagliflozinDapagliflozin 10 mg vs placeboInitiated in-hospital after stabilization (median 3.6 days after admission)Multicenter, randomized, double-blind, placebo-controlled2 monthsComposite of cardiovascular death or worsening heart failure: 10.9% vs 12.7%, HR 0.86 (95% CI 0.68–1.08), P=0.20All-cause death: 3.0% vs 4.5%, HR 0.66 (95% CI 0.43–1.00); symptomatic hypotension: 3.6% vs 2.2%; worsening kidney function: 5.9% vs 4.7%; meta-analysis of in-hospital SGLT2 inhibition initiation: HR for CV death or worsening HF 0.71 (95% CI 0.54–0.93), P=0.012Yeoh et al182023HF with loop diuretic resistance61 (60 analyzed)DapagliflozinDapagliflozin 10 mg vs metolazone 5–10 mgAfter randomization, administered for 3 daysMulticenter, open-label, randomized active-comparator5 days (96 hours)Weight loss at 96h: dapagliflozin −3.0±2.5 kg vs metolazone −3.6±2.0 kg; mean difference 0.65 kg (95% CI −0.12 to 1.41), P=0.11Loop diuretic efficiency (kg/40mg furosemide) at 96h: 0.15±0.12 vs 0.25±0.19, difference −0.08 (−0.17 to 0.01), P=0.10; B-line change: similar; pleural effusion score: similar; safety: less biochemical upset with dapagliflozin (urea and sodium changes significantly smaller)EL-Gazar et al192025AHF with volume overload142 (135 analyzed)Canagliflozin vs EmpagliflozinCanagliflozin 100 mg vs empagliflozin 10 mgWithin 24 hours of admissionMulticenter, prospective, open-label, randomized equivalence trial90 daysMedian daily diuresis: canagliflozin 4200 mL (IQR 3492–4963) vs empagliflozin 4117 mL (3400–5242); median difference 83 mL (95% CI −200 to +366), within equivalence margin ±411.7 mL, bootstrap TOST P<0.001NT-proBNP at discharge (median): canagliflozin 2523 pg/mL vs empagliflozin 3121, P=0.052; at day 30: 1098 vs 1768, P=0.025; KCCQ-TSS change at day 90: +28.61±21.15 vs +20.41±23.02, P=0.044; HF events: 23.9% vs 27%, P=0.684; safety similarMocan et al202025AHF100 (98 analyzed)DapagliflozinDapagliflozin + IV furosemide vs IV furosemide aloneWithin 24 hours of admissionSingle-center, open-label, randomized controlled1 monthChange in lung B-lines at discharge: dapagliflozin −23.80±14.03 vs control −13.96±10.55, P<0.001; at 1 month: −23.80±14.04 vs −13.96±10.55, P<0.001. Weight change: −5.73±5.88 kg vs −4.72±4.91 kg, P=0.10824-h natriuresis: dapagliflozin 248.03±23.69 vs 173.83±20.76, P=0.009; WRF (≥25% creatinine increase): 30.6% vs 12.8%, P=0.048; 1-month EF change: +5.99±10.07% vs +1.46±7.47%, P=0.003; EDV change: −12.54±34.81 vs −4.21±30.91, P=0.033Bogoviku et al212025ADHF60EmpagliflozinEmpagliflozin 25 mg vs placeboWithin 12 hours of admission, for 5 daysProspective, double-blind, randomized, placebo-controlled30 daysSerum uric acid (µmol/L): placebo increased from 488 to 518 at day 4; empagliflozin decreased from 458 to 423 at day 4; day 3 difference P=0.049, day 4 P=0.021, day 5 P=0.037FEUA at day 3: empagliflozin 9.38±1.07% vs placebo 5.49±0.81%, P=0.008; at day 5: 9.71±1.2% vs 8.17±1.1%, P=NS; at 30 days: both similar to baselineBogoviku et al222025ADHF60EmpagliflozinEmpagliflozin 25 mg/day vs placeboWithin 12 hours of admission, for 5 daysSingle-center, prospective, double-blind, randomized, placebo-controlled30 daysLAV reduction:empagliflozin (30.9±27.4; 95% CI 20.1–41.7) vs placebo (10.5 ± 26; 95% CI 0.4–20.5), P<0.001; LAESVI reduction:empagliflozin (15.7±15.2;95% CI9.8–21.6) vs placebo (9.7 ± 10.2; 95% CI 5.7–13.6), P=0.016LVEF: P=0.787; TAPSE: P=0.077; sPAP: P=0.335; E-wave: P=0.229; left atrial strain: P=0.361; all not statistically significantAngermann et al232026AHF (NHF and ADHF)530 (175 NHF, 355 ADHF)EmpagliflozinEmpagliflozin 10 mg vs placeboAfter stabilization, between 24h and 5 days after admission,afterclinical stabilizationMulticenter, randomized, double-blind, placebo-controlledDays 3 and 5 (if still hospitalized), andthen 15, 30, and 90 days after randomizationWin ratio for clinical benefit: NHF 1.29 (95% CI 0.89–1.89); ADHF 1.39 (95% CI 1.07–1.81); Pinteraction = 0.759Diuretic response at day 15 (kg weight loss per mean daily loop diuretic dose): NHF −5.11 (95% CI −7.89 to −2.32) vs ADHF −0.97 (−2.91 to 0.96), Pinteraction=0.017; KCCQ-TSS change at day 90: NHF +2.54 (−4.55 to 9.64), ADHF +5.29 (0.23–10.36); NT-proBNP AUC ratio at day 30: NHF 0.87 (0.75–1.01), ADHF 0.91 (0.82–1.02); safety: fewer AEs with empagliflozinHacil et al242025Elderly patients (mean age 90 years) hospitalized for AHF496Empagliflozin, DapagliflozinSGLT2 inhibition group (n=260) vs Control group (n=236, standard HF treatment without SGLT2 inhibition)Initiated during hospitalization (at discharge)Prospective multicenter observational1 yearAll-cause mortality at 1 year: 28.0% vs 36.8%, adjusted HR 0.67 (95% CI 0.46–0.98), P=0.031; HF rehospitalization: 18.0% vs 30.9%, adjusted HR 0.64 (95% CI 0.42–0.97), P=0.037; composite outcome: 38.4% vs 56.7%, adjusted HR 0.60 (95% CI 0.44–0.82), P=0.001Adverse events: urinary tract infections (14.6% vs 8.9%, OR 1.81, P=0.038), genital infections (7.6% vs 3.5%, OR 2.44, P=0.033); acute renal failure (13.1% vs 14.8%, P=0.58); treatment discontinuation due to adverse events: 5.0% (2.7% due to recurrent genitourinary infections)Mizobuchi et al252023AHF118DapagliflozinEarly initiation (≤6 days after admission) vs late initiation (≥7 days)Initiated during hospitalization at physician’s discretionPost hoc analysis of prospective observational registryin-hospitalLength of hospital stay: early group median 16.5 days (IQR 13–22) vs late group 22 days (IQR 17–27), P=0.002; time to initiation positively correlated with hospital stay (r=0.46, P<0.001)Composite event of rehospitalization for HF and all-cause death at 30 and 90 days: no significant difference between groups (P=0.26 and P=0.83)Wu et al262025AHF with type 2 diabetes (age ≥66)9641SGLT2 inhibition (canagliflozin, dapagliflozin, empagliflozin)Post-discharge SGLT2 inhibitor initiation within 3 days, 4–90 days, or91–180 days, vs delayed initiation for at least 180 days.Timing of initiation: ≤3 days, 4–90 days, 91–180 days vs delayed >180 days post-dischargePopulation-based retrospective cohort (clone-censor-weight approach)1 yearComposite of HHF or CV mortality: ≤3 days vs >180 days: RR 0.65 (95% CI 0.45–0.83); 4–90 days: RR 0.83 (0.72–0.93); 91–180 days: RR 0.89 (0.79–0.97)HHF alone: ≤3 days RR 0.55 (0.34–0.77); CV mortality: ≤3 days RR 0.67 (0.37–1.03); all-cause mortality: ≤3 days RR 0.66 (0.41–0.93); all-cause readmission: ≤3 days RR 0.74 (0.63–0.86)Llorens et al272025AHF3554SGLT2 inhibition (dapagliflozin, empagliflozin)SGLT2 inhibition use at discharge vs no use; new initiation vs chronic usePrescription at discharge after AHF episodeMulticenter, prospective, observational1 year30-day composite adverse event (ED revisit, HF hospitalization, or death): adjusted HR 0.80 (95% CI 0.65–0.99); 1-year mortality: adjusted HR 0.78 (0.63–0.96)New initiation during decompensation: 30-day composite HR 0.65 (0.49–0.87); 1-year mortality HR 0.71 (0.54–0.93); interaction P for 30-day benefit better with new initiation (P=0.02)Carballo et al282020Consecutive patients admitted for ADHF815Dapagliflozin (eligibility criteria based on DAPA-HF)Eligible for dapagliflozin (n=220, LVEF<40% meeting DAPA-HF criteria) vs non-eligible (n=595)/Prospective observational cohortMedian 15 months (IQR 7–25)All-cause mortality or readmission: eligible vs non-eligible, adjusted HR 0.82 (95% CI 0.68–0.999), P=0.049Proportion eligible for dapagliflozin: 27% of all patients; baseline characteristics: eligible patients younger (median 74.4 years), higher eGFR (55 mL/min), higher NT-proBNP (6625 ng/L) vs non-eligibleWu et al292024AHF or acute exacerbation of chronic HF399 (320 after PSM)DapagliflozinDapagliflozin group vs Dapagliflozin-Free groupInitiated within 6 days after admissionRetrospective propensity score-matched cohort90 daysAll-cause readmission at 90 days after PSM: 16.88% vs 18.12%, OR 0.9141 (95% CI 0.5385–1.552), log-rank P=0.739; HF readmission: 11.88% vs 15.00%, OR 0.9077 (95% CI 0.4441–1.469), log-rank P=0.484Loop diuretic daily dose: 20 mg/d vs 30 mg/d, P<0.001; total loop diuretic dose during hospitalization: 106.06±31.23 mg vs 144.50±45.39 mg, P=0.038; adding another class of diuretic: 11.88% vs 23.12%, P=0.008; safety events (renal function deterioration, symptomatic hypotension, hypoglycemia, ketoacidosis) similar between groupsAbbreviations:AHF, acute heart failure; HF:heart failure, ADHF, acute decompensated heart failure; SGLT2, sodium-glucose cotransporter 2; CV, cardiovascular; LVEF, left ventricular ejection fraction; NHF, de novo heart failure; HHF, hospitalization for heart failure; FEUA, fractional excretion of uric acid; ED, emergency departments; VAS, visual analogue scale; IV, intravenous; IQR, interquartile range; PSM, propensity score matching; AUC, area under the curve; NT-proBNP, N-terminalpro-B-type natriuretic peptide; 95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio; WRF, worsening renal function; EF, ejection fraction; EDV, end-diastolic volume; RR, risk ratio; TAPSE, tricuspid annular plane systolic excursion; sPAP, systolic pulmonary artery pressure; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire total symptom score; FEUA, fractional excretion of uric acid; HR, hazard ratio. Summary of Key Clinical Evidence for SGLT2 Inhibitors in Acute or Recently Worsening Heart Failure Abbreviations:AHF, acute heart failure; HF:heart failure, ADHF, acute decompensated heart failure; SGLT2, sodium-glucose cotransporter 2; CV, cardiovascular; LVEF, left ventricular ejection fraction; NHF, de novo heart failure; HHF, hospitalization for heart failure; FEUA, fractional excretion of uric acid; ED, emergency departments; VAS, visual analogue scale; IV, intravenous; IQR, interquartile range; PSM, propensity score matching; AUC, area under the curve; NT-proBNP, N-terminalpro-B-type natriuretic peptide; 95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio; WRF, worsening renal function; EF, ejection fraction; EDV, end-diastolic volume; RR, risk ratio; TAPSE, tricuspid annular plane systolic excursion; sPAP, systolic pulmonary artery pressure; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire total symptom score; FEUA, fractional excretion of uric acid; HR, hazard ratio. Randomized Controlled Trials of in-Hospital or Peri-Discharge Initiation Several randomized controlled trials have evaluated the efficacy and safety of initiating SGLT2 inhibitors during hospitalization or around discharge in patients with AHF or recent worsening heart failure. Empagliflozin was first investigated in the EMPAG-HF trial, in which 60 patients with acute decompensated heart failure were randomized to empagliflozin 25 mg or placebo within 12 hours of admission. Over 5 days, empagliflozin increased cumulative urine output compared with placebo and improved loop diuretic efficiency, without adversely affecting renal function.11 The EMPA-RESPONSE-AHF trial subsequently randomized 80 patients with acute decompensated heart failure to empagliflozin 10 mg or placebo within 24 hours of admission.12 Although empagliflozin did not significantly improve the primary endpoints of dyspnea, diuretic response, or length of hospital stay, it was well tolerated and was associated with increased urine output and a lower rate of the composite endpoint of worsening heart failure, rehospitalization for heart failure, or death at 60 days.12 The EMPULSE trial provided larger-scale randomized evidence for empagliflozin in hospitalized AHF.13 In this trial, 530 patients with de novo or decompensated chronic heart failure were randomized to empagliflozin 10 mg or placebo after clinical stabilization, with a median time to randomization of approximately 3 days after admission. Empagliflozin significantly improved the primary hierarchical composite outcome of all-cause death, heart failure events, and change in Kansas City Cardiomyopathy Questionnaire total symptom score at 90 days, with fewer serious adverse events than placebo.13 These findings support the clinical benefit and tolerability of empagliflozin when initiated after stabilization during hospitalization. Sotagliflozin was evaluated in the SOLOIST-WHF trial, which enrolled 1222 patients with type 2 diabetes and recent worsening heart failure.14 Sotagliflozin was initiated either before discharge or within 3 days after discharge. Over a median follow-up of 9 months, sotagliflozin significantly reduced the total number of cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure.14 Although SOLOIST-WHF was not limited to patients treated strictly during the acute admission period, it provides important evidence supporting SGLT inhibition during the vulnerable peri-discharge phase after worsening heart failure. Dapagliflozin has also been evaluated in several randomized studies. The DAPA-RESPONSE-AHF trial randomized patients with AHF to dapagliflozin or standard care and reported improvements in dyspnea, diuresis, and 30-day rehospitalization with dapagliflozin.15 The DICTATE-AHF trial further showed that dapagliflozin initiated within 24 hours of admission reduced loop diuretic requirements, improved natriuresis, and facilitated earlier discharge without increasing adverse events.16 In contrast, the larger DAPA ACT HF-TIMI 68 trial randomized 2401 patients hospitalized for heart failure to dapagliflozin or placebo at a median of 3.6 days after admission.17 Although dapagliflozin was well tolerated, the primary composite endpoint of cardiovascular death or worsening heart failure at 2 months did not reach statistical significance.17 This neutral primary result is important and indicates that the benefits of in-hospital dapagliflozin initiation should not be overstated. Other randomized studies have provided additional information on decongestion and drug selection. The dapagliflozin versus metolazone trial suggested that dapagliflozin may provide decongestive effects with a more favorable biochemical profile than metolazone in patients with loop diuretic resistance.18 The CANA-AHF trial suggested that canagliflozin had similar short-term effects to empagliflozin on diuresis, NT-proBNP reduction, length of stay, and quality of life in patients with AHF.19 Mocan et al reported that adding dapagliflozin to intravenous loop diuretics improved pulmonary congestion relief, but did not reduce 30-day readmission compared with standard therapy alone.20 Taken together, randomized evidence generally supports the feasibility and safety of SGLT2 inhibitor initiation after clinical stabilization in AHF, especially for decongestion and diuretic efficiency. However, effects on short-term readmission and early hard outcomes remain inconsistent across trials. Trial Subanalyses and Meta-Analytic Evidence Prespecified analyses and secondary analyses of randomized trials have provided additional insight into potential mechanisms, patient subgroups, and intermediate outcomes. In a subanalysis of the EMPAG-HF trial, empagliflozin reduced serum uric acid levels during recompensation for acute heart failure.21 Another echocardiographic subanalysis of EMPAG-HF showed that empagliflozin was associated with favorable changes in left atrial volume and left atrial end-systolic volume index, suggesting potential early hemodynamic effects.22 However, these findings are based on secondary or exploratory endpoints and should be interpreted as hypothesis-generating rather than definitive evidence. A prespecified analysis of EMPULSE showed that the clinical benefit of empagliflozin was consistent in patients with de novo heart failure and those with acute decompensated chronic heart failure.23 This finding is clinically relevant because AHF is a heterogeneous syndrome, and treatment effects may differ between newly diagnosed and recurrent decompensated disease. Nevertheless, subgroup analyses are generally underpowered for definitive conclusions and should be viewed as supportive evidence. The DAPA ACT HF-TIMI 68 trial also included a prespecified meta-analysis incorporating DAPA ACT HF-TIMI 68, EMPULSE, and SOLOIST-WHF, with a total of 3527 patients. This analysis suggested that in-hospital or peri-discharge initiation of SGLT2 inhibitors reduced the early risk of cardiovascular death or worsening heart failure and all-cause mortality.17 This meta-analytic evidence supports a generally favorable direction of effect. However, the neutral primary endpoint of DAPA ACT HF-TIMI 68, differences in trial populations, different timing of initiation, and variable outcome definitions indicate that the magnitude of benefit and the most appropriate target population remain uncertain. Real-World and Observational Evidence Real-world and observational studies complement randomized trials by providing information on broader and more complex patient populations, including elderly patients, multimorbid patients, and patients treated in routine clinical practice. The AGING-HF study evaluated the tolerability of SGLT2 inhibitors in very elderly patients with AHF and multimorbidity, with a mean age of approximately 90 years. The discontinuation rate was low, suggesting that SGLT2 inhibitors may be feasible in carefully selected elderly patients.24 However, because treatment allocation was not randomized, these findings should be interpreted cautiously. A retrospective study by Mizobuchi et al suggested that early initiation of dapagliflozin during hospitalization for AHF was associated with a shorter length of hospital stay.25 Wu et al reported, in a large population-based cohort of patients with AHF and type 2 diabetes, that earlier initiation of SGLT2 inhibitors after discharge was associated with lower 1-year risk of heart failure readmission or cardiovascular death.26 A Spanish multicenter registry study also found that SGLT2 inhibitor use at discharge was associated with lower short-term adverse events and lower 1-year mortality, with greater benefit observed among patients initiated during the acute decompensation episode.27 These studies support the potential value of early initiation in routine clinical practice, but the observational design limits causal inference because residual confounding, indication bias, and treatment selection bias cannot be excluded. Other observational studies have highlighted the importance of patient selection. A real-world cohort study based on DAPA-HF eligibility criteria found that only a minority of AHF patients would have been theoretically eligible for dapagliflozin, and eligible patients had better outcomes than ineligible patients.28 This finding emphasizes that clinical trial populations may not fully represent the broader AHF population encountered in routine practice. Our previous retrospective propensity score-matched cohort study found that dapagliflozin reduced the need for intravenous loop diuretics but did not significantly reduce 90-day all-cause or heart failure-specific readmission.29 This result is consistent with the broader uncertainty regarding short-term readmission outcomes. Overall, real-world evidence supports the feasibility of SGLT2 inhibitor use in selected patients with AHF, but the strength of evidence is limited by the non-randomized nature of most studies. Timing of Initiation and Clinical Implementation The timing of SGLT2 inhibitor initiation is one of the most clinically important unresolved questions in AHF. Existing studies have used different initiation windows. In EMPAG-HF, empagliflozin was initiated within 12 hours of admission.11 In EMPA-RESPONSE-AHF and DAPA-RESPONSE-AHF, treatment was initiated within 24 hours of admission.12,15 In DICTATE-AHF, dapagliflozin was also initiated early during hospitalization, within 24 hours of presentation.16 By contrast, EMPULSE initiated empagliflozin after clinical stabilization, with a median time to randomization of 3 days after admission and DAPA ACT HF-TIMI 68 randomized patients at a median of 3.6 days after admission.13,17 SOLOIST-WHF initiated sotagliflozin before discharge or within 3 days after discharge.14 These data suggest that SGLT2 inhibitors can be considered during the early in-hospital or peri-discharge phase, provided that patients have achieved haemodynamic stabilization. However, the optimal initiation window cannot yet be precisely defined because studies differ in stabilization criteria, timing of randomization, baseline patient risk, background therapies, and outcome definitions. Available evidence favors early initiation after stabilization rather than delayed outpatient initiation, but early use should not be interpreted as immediate administration to all patients at admission. From a practical perspective, SGLT2 inhibitors may be considered once the patient has no persistent hypotension, no need for escalating intravenous vasodilators or vasoactive drugs, no rapidly worsening renal function, no diabetic ketoacidosis, and no active severe genitourinary infection. In patients with persistent haemodynamic instability, cardiogenic shock, severe volume depletion, or rapidly progressive renal dysfunction, initiation should be deferred until clinical stabilization is achieved. Therefore, the key clinical issue is not simply “early versus late” initiation, but identifying the earliest safe time point after stabilization in an appropriately selected patient. Safety Considerations and Patient Selection The overall safety profile of SGLT2 inhibitors in randomized trials of AHF has been reassuring when treatment is initiated after haemodynamic stabilization. In EMPAG-HF, empagliflozin increased urine output and improved diuretic efficiency without worsening renal function.11 In EMPA-RESPONSE-AHF, empagliflozin was well tolerated despite early initiation.12 In EMPULSE, serious adverse events were numerically lower in the empagliflozin group than in the placebo group.13 In DAPA ACT HF-TIMI 68, dapagliflozin was not associated with a significant excess of hypotension, severe renal adverse events, or hyperkalemia.17 These findings support the safety of SGLT2 inhibitors in stabilized AHF patients enrolled in clinical trials. Nevertheless, several safety considerations remain important in clinical practice. First, although SGLT2 inhibitors generally have modest blood pressure-lowering effects, caution is required in patients with symptomatic hypotension, severe volume depletion, cardiogenic shock, or ongoing need for vasoactive support. Second, renal function should be assessed before and after initiation, especially in patients with severe chronic kidney disease, acute kidney injury, or rapidly changing volume status. Third, although diabetic ketoacidosis is uncommon, the risk may increase in patients with prolonged fasting, severe infection, insulin deficiency, perioperative stress, or type 1 diabetes. Fourth, active urinary tract or genital infections should be considered before initiation, and treatment may need to be delayed in patients with severe active infection. Importantly, many high-risk AHF patients were excluded or underrepresented in randomized trials, including those with cardiogenic shock, severe renal impairment, marked hypotension, active ketoacidosis, severe infection, or continuous requirement for vasoactive agents. Therefore, early initiation should not be generalized to all patients with AHF. Instead, SGLT2 inhibitors should be started after careful assessment of haemodynamic stability, renal function, volume status, infection risk, and metabolic status. Future studies are needed to clarify safety boundaries in high-risk populations and to establish more standardized criteria for clinical stabilization. Guideline Recommendations Guideline recommendations have evolved rapidly as evidence from chronic heart failure, worsening heart failure, and AHF studies has accumulated. The 2021 ESC Guidelines incorporated SGLT2 inhibitors as part of foundational therapy for heart failure with reduced ejection fraction, together with angiotensin receptor-neprilysin inhibitors, beta-blockers, and mineralocorticoid receptor antagonists.3 The 2023 ESC focused update further emphasized early guideline-directed medical therapy optimization and supported the use of SGLT2 inhibitors across a broader range of heart failure phenotypes.30 More recently, the 2025 JCS/JHFS Guidelines assigned a class I, level A recommendation to SGLT2 inhibitors in AHF, recommending initiation after haemodynamic stability is achieved.31 The 2025 HFA/HFAI Scientific Statement also recommended dapagliflozin or empagliflozin for heart failure prevention and treatment across heart failure phenotypes, and supported early initiation after stabilization in patients hospitalized with acute decompensation.32 Across recent guidelines and expert statements, a consistent clinical direction has emerged: SGLT2 inhibitors should be considered early after haemodynamic stabilization in eligible patients with AHF. However, the exact timing of initiation, stabilization criteria, and safety boundaries in high-risk populations remain incompletely defined. Therefore, guideline recommendations should be implemented together with individualized assessment of haemodynamic status, renal function, volume status, infection risk, and ketoacidosis risk. Mechanisms by Which SGLT2 Inhibitors Improve Heart Failure Although SGLT2 inhibitors were originally developed as glucose-lowering agents, recent studies have revealed that they exert rapid symptomatic relief and organ protection in acute heart failure through multiple, glucose-independent targets. These mechanisms not only account for their benefit in chronic heart failure but also provide a theoretical rationale for their use during the acute phase of AHF. Nevertheless, the exact mechanisms of SGLT2 inhibitors in AHF remain incompletely defined, current evidence indicates that they produce their effects via integrated, multi-target and multi-pathway actions. Hemodynamic Mechanism Dyspnea caused by excessive fluid overload is the most common presenting symptom of AHF. In this setting, the initial therapeutic goal is to achieve a positive fluid balance without residual fluid retention.33,34 SGLT2 inhibitors promote osmotic diuresis by blocking glucose and sodium reabsorption in the proximal tubule, thereby increasing urinary glucose and sodium excretion. This diuretic effect differs from that of conventional loop diuretics in that it does not rely on renal medullary blood flow and may therefore remain effective even when renal perfusion is reduced.35 The EMPA-RESPONSE-AHF trial showed that AHF patients treated with an SGLT2 inhibitor had a significant increase in 24-hour urine output, without appreciable activation of the RAAS or heightened risk of hypokalemia.12 More recent studies in AHF patients receiving SGLT2 inhibitors have documented greater natriuresis and lower natriuretic peptide levels.11 The enhanced glucosuria-driven osmotic diuresis appears to be the key mechanism underlying this effect, consistent with findings from the EMPA-RESPONSE-AHF study. By promoting the excretion of electrolyte-free water, SGLT2 inhibitors remove fluid more efficiently than agents that deplete the intravascular compartment alone.36 Multicenter randomized trials have demonstrated that initiating dapagliflozin within 24h of AHF onset significantly reduces the cumulative dose of loop diuretics while augmenting natriuresis and urine output in response to intravenous furosemide.16 These data indicate that, in the context of AHF, dapagliflozin enhances diuresis, optimizes ventricular filling conditions, and reduces volume load, thereby helping to maintain hemodynamic stability. Improvement in Myocardial Energy Metabolism In AHF, energy demand of cardiomyocytes rises, yet glucose oxidation is impaired by ischemia and hypoxia, plunging the cells into an energy crisis. SGLT2 inhibitors lower blood glucose by enhancing urinary glucose loss, thereby inducing mild ketosis and shifting cardiac fuel use from glucose to ketone bodies. This switch raises oxygen efficiency and improves energy supply to ischemic myocardium.37 However, ketones do not enhance cardiac efficiency, instead, they accelerate the rate of ATP production.38 Preferential oxidation of ketones also decreases toxic intracellular lipid intermediates, potentially ameliorating cardiac steatosis and left-ventricular remodeling.39 In an AHF rat model, dapagliflozin augmented ketone oxidation while suppressing pyruvate oxidation, improved mitochondrial redox state, and lowered myocardial oxidative stress.40 Other studies show that SGLT2 inhibitors act directly on the heart to enhance mitochondrial function and attenuate oxidative stress, conferring protection in pressure-overload-induced heart failure.41 Moreover, these agents mitigate hypoxia and inflammation, and promote conversion of myofibroblasts into erythropoietin-secreting fibroblasts, thereby delivering more oxygen to support cardiac energy metabolism.42,43 Relief of Congestion Congestion is a principal driver of decompensated heart failure and is therefore an undisputed therapeutic target in AHF. Among hospitalized patients, complete decongestion at discharge and its maintenance during the early post-discharge phase independently predict better outcomes.44,45 Thus, optimizing decongestive therapy is fundamental to preventing subsequent death and heart-failure readmission. SGLT2 inhibitors consistently alleviate congestion in chronic heart failure,46,47 but evidence for such benefit in AHF remains scarce. Early work showed that dapagliflozin reduces interstitial fluid volume more than three-fold relative to the decline in blood volume, whereas bumetanide achieves only a 66% interstitial-to-blood volume reduction.36 The observation that empagliflozin produces greater negative fluid balance without lowering blood pressure in AHF patients supports the notion that increased plasma osmolality stabilizes plasma-refill rate from the interstitium.48 The EMPULSE trial provides the first comprehensive longitudinal evidence that empagliflozin exerts sustained decongestive effects in patients hospitalized for AHF.13 Furthermore, empagliflozin appears to act through mechanisms distinct from-or complementary to-hose of loop diuretics, suggesting an additive decongestive role in the acute setting.13,48 Additional Mechanisms A systematic review and meta-analysis of the safety and efficacy of dapagliflozin in AHF reported a significant reduction in body weight among treated patients.49 This weight loss is attributable primarily to the diuretic effect of dapagliflozin, which decreases fluid retention, and to its impact on glucose and lipid metabolism that promotes fat loss.50 In addition to weight reduction, modest declines in blood pressure and plasma uric acid levels were observed,51 both advantageous in heart-failure management because they lessen cardiac workload. The potential benefits of SGLT2 inhibitors in AHF may also relate to improvements in cardiopulmonary fitness, volume status (without RAAS activation), and metabolic flexibility.52 Similarly, anti-inflammatory responses, diminished reactive oxygen species, better endothelial function, and neuro-modulatory effects have been described, although their relative importance remains to be further elucidated.53–56 In the specific context of AHF, these multiple mechanisms do not act in isolation or slowly, but instead exhibit rapid onset and synergistic effects. For example, the osmotic diuretic effect can quickly relieve pulmonary congestion and dyspnea within hours, while improvements in myocardial energy metabolism and reduction of inflammatory responses may exert protective effects against myocardial injury over days to weeks. Conclusions and Future Directions SGLT2 inhibitors have evolved from glucose-lowering agents into cornerstone therapy for chronic heart failure, and their application has gradually expanded to the setting of AHF. Current evidence suggests that early initiation of SGLT2 inhibitors after haemodynamic stabilization may help relieve congestion, enhance diuretic efficiency, and reduce the risk of heart failure events in selected patients with AHF. However, several key issues remain unresolved. First, the optimal timing of initiation has not been standardized, and the definition of haemodynamic stabilization varies across studies and guidelines; the benefits and risks of initiation within the first 24 hours after admission require further clarification. Second, safety data remain limited in high-risk populations, including patients with cardiogenic shock, severe renal impairment, persistent hypotension, active infection, or ongoing requirement for vasoactive agents. Third, findings regarding short-term readmission remain inconsistent across studies. Future large-scale randomized trials and well-designed real-world studies are needed to define the optimal initiation window, standardize clinical stabilization criteria, and systematically evaluate the risk-benefit profile in high-risk populations. These efforts may further clarify the role of SGLT2 inhibitors in the management of AHF.